NEW

VA Selects Philips to Create World’s Largest Tele-Critical Care System

Royal Philips has announced that the U.S. Department of Veterans Affairs (VA) has awarded a contract to Philips to expand VA’s tele-critical care program, creating the world’s largest system to provide veterans remote access to intensive care expertise, regardless of...

BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation

BD (Becton, Dickinson and Company) has announced the availability of BD PurPrep patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83%...

PDI Receives Promising Testing Results of Super Sani-Cloth Wipes Against SARS-COV-2

PDI has generated data showing its Super Sani-Cloth wipes are effective against SARS-CoV-2, the virus that causes COVID-19. This is one of several of the company's hospital-grade disinfecting products being tested for efficacy against SARS-CoV-2 for submission to the...

New Dräger Solution Aims to Improve Long-Term Acute Care Outcomes

Dräger has leveraged its 100+ years of critical care expertise to develop a new solution designed specifically to address the needs of the long-term acute care (LTAC) environment. With Dräger’s solution, LTAC facilities can maintain quality throughout the continuum of...

Virtual Incision Announces $20M Financing to Advance Surgical Mini-Robot

Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical robot, has raised $20 million in a Series B+ financing led by returning investor Bluestem Capital, with participation from returning investor PrairieGold Venture Partners, as well as from Genesis Innovation Group and other affiliated investors. The funds will support regulatory and clinical programs leading to the commercialization of the company’s MIRA (“miniaturized in vivo robotic assistant”) Surgical Robotic Platform.

Virtual Incision also announced its filing for an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA). An IDE approval will allow the company to initiate a confirmatory clinical study of the MIRA Surgical Robotic Platform in support of regulatory pathway to approval. The study will evaluate the safety and efficacy of the MIRA platform for colon resection surgeries in patients at a number of U.S. investigational sites.

MIRA is an investigational robot that will enable surgeons to perform minimally invasive surgeries in any hospital or surgery center, without the need for a dedicated space or for the infrastructure typically required for other “mainframe” robotic systems. Weighing only two pounds, the miniature single incision platform has full robotic capabilities, and can easily be moved from room to room.

Virtual Incision’s goal is to increase patients’ access to minimally invasive abdominal surgery and to maximize hospital efficiency in various settings at a price point significantly lower than currently available robotic systems.

“We designed the MIRA Surgical Robotic Platform with the fundamental understanding that minimally invasive procedures offer tremendous benefits to patients. We believe our portable and affordable abdominal robot has the potential to bring these benefits to many more patients,” said John Murphy, president and CEO of Virtual Incision. “The planned IDE clinical study of MIRA is the critical next step for the company.”

“Beyond our initial device design for colon resection, Virtual Incision has begun developing a family of procedure-specific mini-robots for additional operations such as hernia repair, gallbladder removal and others, potentially enabling millions more surgical procedures each year,” said Shane Farritor, Ph.D., Virtual Incision’s co-founder and chief technology officer.

“The Virtual Incision team has developed a unique robotic platform that has incredible potential to transform surgery,” said Steve Kirby, founding partner, Bluestem Capital. “With its foundational intellectual property – including more than 200 patents and applications – we are convinced that Virtual Incision will be leading the next wave of innovation in robotic surgery with the pioneering MIRA system.”

“Demand for minimally invasive surgeries continues to increase, and we are enthusiastic about the promise of the MIRA platform to meet this demand, while also delivering unparalleled flexibility,” said Dmitry Oleynikov, M.D., Virtual Incision’s co-founder and chief medical officer. “We are focused on expanding access to minimally invasive robotic procedures and delivering this innovation to the many centers where a smaller, simpler and less costly solution is needed.”

The MIRA Surgical Robotic Platform is an investigational device that is not available for sale in the United States.

For more information, visit virtualincision.com.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X